- Home
- ENX vs CRBU Comparison
ENX vs CRBU Comparison
Compare ENX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- CRBU
- Stock Information
- Founded
- ENX 2002
- CRBU 2011
- Country
- ENX United States
- CRBU United States
- Employees
- ENX N/A
- CRBU N/A
- Industry
- ENX Finance/Investors Services
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ENX Finance
- CRBU Health Care
- Exchange
- ENX Nasdaq
- CRBU Nasdaq
- Market Cap
- ENX 169.0M
- CRBU 188.8M
- IPO Year
- ENX N/A
- CRBU 2021
- Fundamental
- Price
- ENX $9.39
- CRBU $1.85
- Analyst Decision
- ENX
- CRBU Strong Buy
- Analyst Count
- ENX 0
- CRBU 3
- Target Price
- ENX N/A
- CRBU $6.67
- AVG Volume (30 Days)
- ENX 25.4K
- CRBU 1.2M
- Earning Date
- ENX 01-01-0001
- CRBU 08-12-2025
- Dividend Yield
- ENX 3.94%
- CRBU N/A
- EPS Growth
- ENX N/A
- CRBU N/A
- EPS
- ENX 0.16
- CRBU N/A
- Revenue
- ENX N/A
- CRBU $9,121,000.00
- Revenue This Year
- ENX N/A
- CRBU $9.52
- Revenue Next Year
- ENX N/A
- CRBU N/A
- P/E Ratio
- ENX $61.00
- CRBU N/A
- Revenue Growth
- ENX N/A
- CRBU N/A
- 52 Week Low
- ENX $7.84
- CRBU $0.66
- 52 Week High
- ENX $10.07
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- ENX 57.20
- CRBU 49.68
- Support Level
- ENX $9.28
- CRBU $1.73
- Resistance Level
- ENX $9.48
- CRBU $2.09
- Average True Range (ATR)
- ENX 0.11
- CRBU 0.15
- MACD
- ENX 0.00
- CRBU -0.03
- Stochastic Oscillator
- ENX 22.77
- CRBU 46.94
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.